Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Delay could affect Amgen’s timeline for a potential filing of a preliminary injunction in its case against Roche, slated for trial in September.
You may also be interested in...
Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia
Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.
Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia
Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.
Epoetin Alfa Increases Cardiovascular Risks When Targeting High Hemoglobin Levels, J&J Study Finds
Patients with chronic kidney disease, when treated with a more aggressive dose of Procrit, had a higher risk but no incremental improvement in quality of life.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: